23-valent pneumococcal polysaccharide vaccine. WHO position paper. - National Genomics Data Center (CNCB-NGDC)

Advanced Search

23-valent pneumococcal polysaccharide vaccine. WHO position paper.

No authors listed.

PMID: 18927997

No abstract text available.

Adult

Aged

Cost-Benefit Analysis

Disease Outbreaks

Humans

Infant

Pneumococcal Infections

Pneumococcal Vaccines

Streptococcus pneumoniae

23-valent pneumococcal capsular polysaccharide vaccine

Pneumococcal Vaccines

Journal Article

23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia.23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia.Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly.Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide vaccine in the era of combination antiretroviral therapy.Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children.Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China.Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska native adults.Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013-2017.[Effectiveness of 23-valent pneumococcal polysaccharide vaccine on adult pneumococcal disease].

Efficacy of pneumococcal polysaccharide vaccine.Bridging the gap: need for a data repository to support vaccine prioritization efforts.Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in 2 to 70 year old healthy people in China: A phase III double blind, randomized clinical trial.[Vaccine-related adverse reactions in immunocompromised patients and in special situations of a hospital Vaccine Unit].Vaccination pattern of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Hangzhou, China: a coverage and adverse events following immunization of different age groups.Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly.Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease After Introduction Into Routine Pediatric Use.National routine adult immunisation programmes among World Health Organization Member States: an assessment of health systems to deploy COVID-19 vaccines.Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial.Development of primary invasive pneumococcal disease caused by serotype 1 pneumococci is driven by early increased type I interferon response in the lung.

See all "Cited by" articles